Lupin Limited Logo

Lupin Limited

LUPIN.NS

(1.5)
Stock Price

2.034,30 INR

0% ROA

16.4% ROE

44.65x PER

Market Cap.

1.011.246.223.850,00 INR

0% DER

0.36% Yield

11.03% NPM

Lupin Limited Stock Analysis

Lupin Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Lupin Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (34%), which means it has a small amount of debt compared to the ownership it holds

2 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

3 ROE

ROE in an average range (3.59%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 ROA

The stock's ROA (2.31%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (4.47x) suggests it's overvalued, potentially making it an expensive investment.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

10 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-77.134) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Lupin Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Lupin Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Lupin Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Lupin Limited Revenue
Year Revenue Growth
2003 12.152.000.000
2004 12.611.400.000 3.64%
2005 16.954.000.000 25.61%
2006 20.137.100.000 15.81%
2007 27.063.700.000 25.59%
2008 37.758.800.000 28.32%
2009 47.405.200.000 20.35%
2010 57.068.200.000 16.93%
2011 70.829.100.000 19.43%
2012 94.499.900.000 25.05%
2013 110.886.600.000 14.78%
2014 125.859.900.000 11.9%
2015 136.816.000.000 8.01%
2016 169.928.500.000 19.49%
2017 155.522.400.000 -9.26%
2018 163.693.700.000 4.99%
2019 151.428.000.000 -8.1%
2020 149.269.900.000 -1.45%
2021 161.927.900.000 7.82%
2022 162.699.800.000 0.47%
2023 197.569.200.000 17.65%
2023 196.563.400.000 -0.51%
2024 224.013.200.000 12.25%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Lupin Limited Research and Development Expenses
Year Research and Development Expenses Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 7.098.400.000 100%
2013 9.294.100.000 23.62%
2014 10.987.800.000 15.41%
2015 16.037.800.000 31.49%
2016 23.100.900.000 30.57%
2017 17.075.700.000 -35.29%
2018 15.012.600.000 -13.74%
2019 15.537.900.000 3.38%
2020 14.324.200.000 -8.47%
2021 14.023.600.000 -2.14%
2022 12.800.100.000 -9.56%
2023 0 0%
2023 14.239.200.000 100%
2024 14.000.000.000 -1.71%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Lupin Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 2.608.100.000
2004 3.507.100.000 25.63%
2005 4.769.600.000 26.47%
2006 5.694.100.000 16.24%
2007 7.991.200.000 28.75%
2008 10.359.200.000 22.86%
2009 13.303.300.000 22.13%
2010 16.353.300.000 18.65%
2011 11.358.300.000 -43.98%
2012 3.674.900.000 -209.08%
2013 4.570.800.000 19.6%
2014 3.871.100.000 -18.07%
2015 6.225.700.000 37.82%
2016 6.629.900.000 6.1%
2017 6.005.500.000 -10.4%
2018 6.934.000.000 13.39%
2019 9.381.700.000 26.09%
2020 8.634.000.000 -8.66%
2021 9.154.300.000 5.68%
2022 10.487.800.000 12.71%
2023 0 0%
2023 13.873.500.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Lupin Limited EBITDA
Year EBITDA Growth
2003 2.732.300.000
2004 1.568.300.000 -74.22%
2005 2.976.600.000 47.31%
2006 4.912.800.000 39.41%
2007 6.423.000.000 23.51%
2008 7.438.900.000 13.66%
2009 9.980.900.000 25.47%
2010 11.999.600.000 16.82%
2011 14.980.900.000 19.9%
2012 22.663.400.000 33.9%
2013 31.328.900.000 27.66%
2014 38.610.000.000 18.86%
2015 37.943.100.000 -1.76%
2016 47.890.400.000 20.77%
2017 31.993.100.000 -49.69%
2018 31.157.900.000 -2.68%
2019 29.013.200.000 -7.39%
2020 25.953.200.000 -11.79%
2021 23.484.100.000 -10.51%
2022 18.714.800.000 -25.48%
2023 38.326.400.000 51.17%
2023 39.306.900.000 2.49%
2024 51.454.400.000 23.61%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Lupin Limited Gross Profit
Year Gross Profit Growth
2003 5.927.400.000
2004 6.170.400.000 3.94%
2005 8.694.800.000 29.03%
2006 10.816.300.000 19.61%
2007 15.425.700.000 29.88%
2008 21.715.700.000 28.97%
2009 27.711.000.000 21.64%
2010 34.688.900.000 20.12%
2011 44.790.100.000 22.55%
2012 56.636.100.000 20.92%
2013 69.925.500.000 19.01%
2014 80.643.000.000 13.29%
2015 88.805.200.000 9.19%
2016 113.895.900.000 22.03%
2017 98.038.700.000 -16.17%
2018 100.586.300.000 2.53%
2019 91.706.500.000 -9.68%
2020 90.104.400.000 -1.78%
2021 91.047.400.000 1.04%
2022 94.902.200.000 4.06%
2023 129.458.400.000 26.69%
2023 130.128.700.000 0.52%
2024 105.480.800.000 -23.37%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Lupin Limited Net Profit
Year Net Profit Growth
2003 1.393.100.000
2004 922.200.000 -51.06%
2005 1.729.900.000 46.69%
2006 3.085.600.000 43.94%
2007 4.082.500.000 24.42%
2008 5.015.400.000 18.6%
2009 6.816.300.000 26.42%
2010 8.625.500.000 20.98%
2011 8.676.500.000 0.59%
2012 13.141.600.000 33.98%
2013 18.363.700.000 28.44%
2014 24.032.400.000 23.59%
2015 22.706.900.000 -5.84%
2016 25.574.600.000 11.21%
2017 2.512.600.000 -917.85%
2018 6.065.500.000 58.58%
2019 -2.693.900.000 325.16%
2020 12.165.300.000 122.14%
2021 -15.280.400.000 179.61%
2022 4.300.800.000 455.29%
2023 19.586.800.000 78.04%
2023 19.144.800.000 -2.31%
2024 32.052.400.000 40.27%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Lupin Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 2
2004 2 0%
2005 4 50%
2006 8 42.86%
2007 10 30%
2008 12 16.67%
2009 16 20%
2010 19 21.05%
2011 19 0%
2012 29 34.48%
2013 41 27.5%
2014 54 24.53%
2015 50 -6%
2016 57 10.71%
2017 6 -1020%
2018 13 61.54%
2019 -6 360%
2020 27 119.23%
2021 -34 178.79%
2022 9 466.67%
2023 43 79.07%
2023 42 -2.38%
2024 70 40%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Lupin Limited Free Cashflow
Year Free Cashflow Growth
2003 3.073.100.000
2004 -366.400.000 938.73%
2005 484.600.000 175.61%
2006 6.000.000 -7976.67%
2007 238.300.000 97.48%
2008 1.296.300.000 81.62%
2009 55.600.000 -2231.47%
2010 3.682.700.000 98.49%
2011 5.591.200.000 34.13%
2012 6.999.200.000 20.12%
2013 14.752.900.000 52.56%
2014 18.618.700.000 20.76%
2015 -61.846.900.000 130.1%
2016 14.779.600.000 518.46%
2017 1.977.700.000 -647.31%
2018 6.806.200.000 70.94%
2019 7.957.100.000 14.46%
2020 11.441.400.000 30.45%
2021 -5.377.700.000 312.76%
2022 3.973.600.000 235.34%
2023 27.194.600.000 85.39%
2023 0 0%
2024 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Lupin Limited Operating Cashflow
Year Operating Cashflow Growth
2003 3.910.200.000
2004 925.600.000 -322.45%
2005 1.315.200.000 29.62%
2006 1.779.400.000 26.09%
2007 2.585.300.000 31.17%
2008 4.695.400.000 44.94%
2009 6.764.100.000 30.58%
2010 7.969.200.000 15.12%
2011 5.591.200.000 -42.53%
2012 12.510.300.000 55.31%
2013 20.039.300.000 37.57%
2014 27.330.500.000 26.68%
2015 -3.689.700.000 840.72%
2016 41.147.500.000 108.97%
2017 17.511.900.000 -134.97%
2018 16.659.700.000 -5.12%
2019 14.688.400.000 -13.42%
2020 18.217.600.000 19.37%
2021 3.673.100.000 -395.97%
2022 18.969.800.000 80.64%
2023 36.483.600.000 48%
2023 0 0%
2024 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Lupin Limited Capital Expenditure
Year Capital Expenditure Growth
2003 837.100.000
2004 1.292.000.000 35.21%
2005 830.600.000 -55.55%
2006 1.773.400.000 53.16%
2007 2.347.000.000 24.44%
2008 3.399.100.000 30.95%
2009 6.708.500.000 49.33%
2010 4.286.500.000 -56.5%
2011 0 0%
2012 5.511.100.000 100%
2013 5.286.400.000 -4.25%
2014 8.711.800.000 39.32%
2015 58.157.200.000 85.02%
2016 26.367.900.000 -120.56%
2017 15.534.200.000 -69.74%
2018 9.853.500.000 -57.65%
2019 6.731.300.000 -46.38%
2020 6.776.200.000 0.66%
2021 9.050.800.000 25.13%
2022 14.996.200.000 39.65%
2023 9.289.000.000 -61.44%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Lupin Limited Equity
Year Equity Growth
2003 4.315.800.000
2004 4.905.800.000 12.03%
2005 6.248.600.000 21.49%
2006 8.733.100.000 28.45%
2007 12.891.300.000 32.26%
2008 14.390.700.000 10.42%
2009 25.933.200.000 44.51%
2010 33.325.900.000 22.18%
2011 40.851.800.000 18.42%
2012 52.636.300.000 22.39%
2013 69.985.100.000 24.79%
2014 88.981.600.000 21.35%
2015 110.164.500.000 19.23%
2016 135.320.900.000 18.59%
2017 136.171.400.000 0.62%
2018 137.890.900.000 1.25%
2019 125.811.600.000 -9.6%
2020 138.581.100.000 9.21%
2021 122.219.800.000 -13.39%
2022 125.428.200.000 2.56%
2023 143.734.500.000 12.74%
2023 133.070.000.000 -8.01%
2024 143.734.500.000 7.42%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Lupin Limited Assets
Year Assets Growth
2003 12.300.100.000
2004 13.542.600.000 9.17%
2005 20.437.300.000 33.74%
2006 22.629.900.000 9.69%
2007 33.638.000.000 32.73%
2008 41.341.700.000 18.63%
2009 50.854.600.000 18.71%
2010 61.259.500.000 16.98%
2011 79.340.200.000 22.79%
2012 89.138.600.000 10.99%
2013 102.060.300.000 12.66%
2014 131.377.400.000 22.32%
2015 224.377.500.000 41.45%
2016 266.072.800.000 15.67%
2017 263.053.800.000 -1.15%
2018 279.493.700.000 5.88%
2019 249.838.500.000 -11.87%
2020 236.104.400.000 -5.82%
2021 218.212.200.000 -8.2%
2022 229.559.300.000 4.94%
2023 239.971.800.000 4.34%
2023 234.436.500.000 -2.36%
2024 0 0%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Lupin Limited Liabilities
Year Liabilities Growth
2003 7.984.300.000
2004 8.636.800.000 7.55%
2005 14.188.700.000 39.13%
2006 13.896.800.000 -2.1%
2007 20.746.700.000 33.02%
2008 26.951.000.000 23.02%
2009 24.921.400.000 -8.14%
2010 27.933.600.000 10.78%
2011 38.488.400.000 27.42%
2012 36.502.300.000 -5.44%
2013 32.075.200.000 -13.8%
2014 42.395.800.000 24.34%
2015 114.213.000.000 62.88%
2016 130.751.900.000 12.65%
2017 126.882.400.000 -3.05%
2018 141.602.800.000 10.4%
2019 124.026.900.000 -14.17%
2020 97.523.300.000 -27.18%
2021 95.992.400.000 -1.59%
2022 104.131.100.000 7.82%
2023 96.237.300.000 -8.2%
2023 101.366.500.000 5.06%
2024 0 0%

Lupin Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
449.96
Net Income per Share
49.65
Price to Earning Ratio
44.65x
Price To Sales Ratio
4.93x
POCF Ratio
100.06
PFCF Ratio
100.11
Price to Book Ratio
7.03
EV to Sales
5.03
EV Over EBITDA
23.78
EV to Operating CashFlow
102.13
EV to FreeCashFlow
102.13
Earnings Yield
0.02
FreeCashFlow Yield
0.01
Market Cap
1.011,25 Bil.
Enterprise Value
1.031,59 Bil.
Graham Number
593.44
Graham NetNet
44.63

Income Statement Metrics

Net Income per Share
49.65
Income Quality
0.45
ROE
0.16
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0.79
EBT Per Ebit
0.91
Ebit per Revenue
0.15
Effective Tax Rate
0.2

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.07
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.61
Operating Profit Margin
0.15
Pretax Profit Margin
0.14
Net Profit Margin
0.11

Dividends

Dividend Yield
0
Dividend Yield %
0.36
Payout Ratio
0
Dividend Per Share
8

Operating Metrics

Operating Cashflow per Share
22.16
Free CashFlow per Share
22.16
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.17
Return on Tangible Assets
0
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
44,63
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
315.27
Interest Debt per Share
6.45
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.47
Current Ratio
0
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
20,35 Bil.
Invested Capital
20345300000
Working Capital
20,35 Bil.
Intangibles to Total Assets
0
Average Receivables
23,68 Bil.
Average Payables
14,79 Bil.
Average Inventory
24769500000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Lupin Limited Dividends
Year Dividends Growth
2002 5
2003 5 0%
2004 7 16.67%
2005 7 0%
2006 7 0%
2007 5 -20%
2008 10 50%
2009 13 16.67%
2010 14 7.69%
2011 3 -333.33%
2012 3 0%
2013 4 25%
2014 6 33.33%
2015 8 14.29%
2016 8 0%
2017 8 0%
2018 5 -40%
2019 5 0%
2020 6 16.67%
2021 7 0%
2022 4 -50%
2023 4 0%
2024 8 50%

Lupin Limited Profile

About Lupin Limited

Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is also involved in the provision of biosimilar and over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited network consists of 18 labs, 280 LupiMitra collection centers, and 450 pick-up points. It operates in India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

CEO
Ms. Vinita D. Gupta
Employee
19.210
Address
Kalpataru Inspire
Mumbai, 400055

Lupin Limited Executives & BODs

Lupin Limited Executives & BODs
# Name Age
1 Mr. Amit Kumar Gupta
Company Secretary & Compliance Officer
70
2 Mr. Ramesh Swaminathan
Executive Director, Global Chief Financial Officer, CRO & Head of API Plus SBU
70
3 Ms. Rajalakshmi Azariah
Vice President & Global Head of Corporate Communications
70
4 Mr. Nilesh Deshbandhu Gupta
MD & Executive Director
70
5 Dr. Shahin Fesharaki
Global Chief Scientific Officer
70
6 Dr. Sofia Mumtaz
President of Legal and Compliance of Australia, Japan & Canada Business
70
7 Mr. Christoph Funke
Chief Technical Operations Officer
70
8 Mr. Sreeji Gopinathan
Chief Information Officer
70
9 Mr. Ravi Agrawal
Senior Vice President of Investor Relations and M&A
70
10 Ms. Vinita D. Gupta
Chief Executive Officer & Executive Director
70

Lupin Limited Competitors

Aurobindo Pharma Limited Logo
Aurobindo Pharma Limited

AUROPHARMA.NS

(2.5)
Cipla Limited Logo
Cipla Limited

CIPLA.NS

(3.0)